What is he best known for?
The fields of study he is best known for:
- Cancer
- Pathology
- Internal medicine
His scientific interests lie mostly in Pathology, Carcinoma, Thyroid, Immunohistochemistry and Thyroid carcinoma.
All of his Pathology and Differential diagnosis, Malignancy, Biopsy, Neoplasm and Thymic carcinoma investigations are sub-components of the entire Pathology study.
His studies deal with areas such as Solitary fibrous tumor, Fibroma, Anatomy, Tumor progression and Radiation therapy as well as Differential diagnosis.
The Carcinoma study combines topics in areas such as Posterior cranial fossa, Cancer, Abdominal cavity, Abdomen and Histology.
Juan Rosai has included themes like CD34 and Adult patients in his Immunohistochemistry study.
His studies in Thyroid carcinoma integrate themes in fields like Anatomical pathology and Lymph node.
His most cited work include:
- Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology (794 citations)
- Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. (527 citations)
- Malignant small cell tumor of the thoracopulmonary region in childhood. A distinctive clinicopathologic entity of uncertain histogenesis (501 citations)
What are the main themes of his work throughout his whole career to date?
Juan Rosai mainly investigates Pathology, Immunohistochemistry, Thyroid, Carcinoma and Sarcoma.
The various areas that Juan Rosai examines in his Pathology study include Thyroid carcinoma and Anatomy.
He studies Histogenesis, a branch of Immunohistochemistry.
His Thyroid study is mostly concerned with Thyroid cancer and Thyroglobulin.
As part of his studies on Carcinoma, Juan Rosai frequently links adjacent subjects like Cancer.
His studies link Karyotype with Sarcoma.
He most often published in these fields:
- Pathology (80.27%)
- Immunohistochemistry (15.20%)
- Thyroid (13.07%)
What were the highlights of his more recent work (between 2006-2019)?
- Pathology (80.27%)
- Thyroid (13.07%)
- Thyroid carcinoma (9.07%)
In recent papers he was focusing on the following fields of study:
Pathology, Thyroid, Thyroid carcinoma, Carcinoma and Thyroid cancer are his primary areas of study.
His research in Differential diagnosis, Immunohistochemistry, Lymph node, Anatomical pathology and Thymic carcinoma are components of Pathology.
His research in Differential diagnosis intersects with topics in Internal medicine, Endocrinology and Atypia.
His Thyroid research is multidisciplinary, incorporating elements of Cancer, Poorly differentiated, Malignancy and Nodule.
His Thyroid carcinoma research integrates issues from Observer variation and Incidence.
The concepts of his Thyroid cancer study are interwoven with issues in Radiology and Thyroidectomy.
Between 2006 and 2019, his most popular works were:
- Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology (794 citations)
- Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. (378 citations)
- A Large Multicenter Correlation Study of Thyroid Nodule Cytopathology and Histopathology (243 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Pathology
Juan Rosai mainly focuses on Pathology, Thyroid, Carcinoma, Thyroid carcinoma and Thyroid cancer.
His Pathology research focuses on Malignancy, Lymph node, Thymic carcinoma, Thymoma and Anatomical pathology.
His work carried out in the field of Thyroid brings together such families of science as Phenotype, Cellular differentiation, Oncocytic Neoplasm and Nodule.
Juan Rosai combines subjects such as Thymic Basaloid Carcinoma and Multilocular Thymic Cyst with his study of Carcinoma.
His Thyroid carcinoma research integrates issues from Iodine intake and Incidence.
His Thyroid cancer research includes elements of Radiology and Thyroidectomy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
